Neurocognition and its influencing factors in the treatment of schizophrenia - Effects of aripiprazole, olanzapine, quetiapine and risperidone

Human Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 116-125

  Riedel, M ^a   Schennach Wolff, R ^a   Musil, R ^a   Dehning, S ^a   Cerovecki, A ^a   Opgen Rhein, M ^a   Matz, J ^a   Seemuller F ^a   Obermeier, M ^a   Engel, R R ^a   Muller N ^a   Moller H J ^a   Spellmann, I ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atypical antipsychotics; Influencing variables; Neurocognitive deficits; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; DIAZEPAM; LORAZEPAM; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZOPICLONE;

ADULT; AGE DISTRIBUTION; AGED; AKATHISIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HOSPITAL ADMISSION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY; NEGATIVE SYNDROME; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SLEEP DISORDER;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGING; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INTERACTIONS; HUMANS; MEMORY; MEMORY DISORDERS; MIDDLE AGED; NEURONS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 77749252648     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1101     Document Type: Article

References (67)

1. Akdede BB, nil Yagcioglu AE, Alptekin K, et al. 2006. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 67: 1912-1919.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington DC.
3. Bhatia T, Garg K, Pogue-Geile M, Nimgaonkar VL, Deshpande SN. 2009. Executive functions and cognitive deficits in schizophrenia: comparisons between probands, parents and controls in India. J Postgrad Med 55: 3-7.
4. Bilder RM, Goldman RS, Volavka J, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028.
5. Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A. 2004. Relationship between psychopathology and cognitive functioning in schizophrenia. Compr Psychiatry 45: 392-400.
6. Brazo P, Marie RM, Halbecq I, et al. 2002. Cognitive patterns in subtypes of schizophrenia. Eur Psychiatry 17: 155-162.
7. Brebion G, Smith MJ, Amador X, Malaspina D, Gorman JM. 1997. Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. Am J Psychiatry 154: 1538-1543.
8. Chen EY, Lam LC, Chen RY, Nguyen DG, Chan CK. 1996. Prefrontal neuropsychological impairment and illness duration in schizophrenia: a study of 204 patients in Hong Kong. Acta Psychiatr Scand 93: 144-150.
9. Cording C. 1998. Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 25: 175-178.
10. Cuesta MJ, Peralta V, Zarzuela A. 2001. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17-28.
11. Davidson M, Galderisi S, Weiser M, et al. 2009. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675-682.
12. Dominguez MG, ViechtbauerW, Simons CJ, van OJ, Krabbendam L. 2009. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 135: 157-171.
13. Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. 2009. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol.
14. Fahrmeir L, Kneib T, Lang S. 2007. Linear regression models. Regression; Modelle, Methoden und Anwendungen. Springer Verlag: Heidelberg; 59-188.
15. Fucetola R, Seidman LJ, Kremen WS, Faraone SV, Goldstein JM, Tsuang MT. 2000. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 48: 137-146.
16. Giovagnoli AR, Del PM, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. 1996. Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17: 305-309.
17. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. 1997. Auditory working memory andWisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54: 159-165.
18. Goldberg TE, Goldman RS, Burdick KE, et al. 2007. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122.
19. Good KP, Kiss I, Buiteman C, et al. 2002. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry Suppl 43: s45-s49.
20. Green MF. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
21. Gutbrod K, Cohen R, Mager B, Meier E. 1989. Coding and recall of categorized material in aphasics. J Clin Exp Neuropsychol 11: 821-841.
22. GuyW. 1976. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, National Institute of Mental Health, Rockville, MD (revised).
23. Halari R, Mehrotra R, Sharma T, Kumari V. 2006. Does self-perceived mood predict more variance in cognitive performance than clinician-rated symptoms in schizophrenia? Schizophr Bull 32: 751-757.
24. Harvey PD, Green MF, McGurk SR, Meltzer HY. 2003. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169: 404-411.
25. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. 2006. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 163: 1918-1925 .
26. Hawkins KA. 1999. Memory deficits in patients with schizophrenia: preliminary data from theWechsler Memory Scale-Third Edition support earlier findings. J Psychiatry Neurosci 24: 341-347.
27. Heaton R, Paulsen JS, McAdams LA, et al. 1994. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry 51: 469-476.
28. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. 2001. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58: 24-32.
29. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. 2004. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res 68: 1-9.
30. Hill SK, Bishop JR, Palumbo D, Sweeney JA. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10: 43-57.
31. Holthausen EA, Wiersma D, Knegtering RH, Van den Bosch RJ. 1999. Psychopathology and cognition in schizophrenia spectrum disorders: the role of depressive symptoms. Schizophr Res 39: 65-71.
32. Houthoofd SA, Morrens M, Sabbe BG. 2008. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 30: 1565-1589.
33. Hughes C, Kumari V, Soni W, et al. 2003. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 59: 137-146.
34. Jerrell JM, Ramirez PM. 2008. Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications. Hum Psychopharmacol 23: 595-604.
35. Kay SR, Opler LA, Lindenmayer JP. 1988. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23: 99-110.
36. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. 2004. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68: 283-297.
37. Keefe RS, Roitman SE, Harvey PD, et al. 1995. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 17: 25-33.
38. Keefe RS, Sweeney JA, Gu H, et al. 2007. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1061-1071.
39. Kern RS, Green MF, Cornblatt BA, et al. 2006. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187: 312-320.
40. Kirkpatrick B, Fenton WS, Carpenter WT, Jr, Marder SR. 2006. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214-219.
41. Klingberg S, Wittorf A, Sickinger S, Buchkremer G, Wiedemann G. 2008. Course of cognitive functioning during the stabilization phase of schizophrenia. J Psychiatr Res 42: 259-267.
42. Kohler C, Gur RC, Swanson CL, Petty R, Gur RE. 1998. Depression in schizophrenia: I. Association with neuropsychological deficits. Biol Psychiatry 43: 165-172.
43. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. 2007. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 68: 368-379.
44. LoSasso GL, Rapport LJ, Axelrod BN, Reeder KP. 1998. Intermanual and alternate-form equivalence on the trail making tests. J Clin Exp Neuropsychol 20: 107-110.
45. Mockler D, Riordan J, Sharma T. 1997. Memory and intellectual deficits do not decline with age in schizophrenia. Schizophr Res 26: 1-7.
46. Moreno SG, Sutton AJ, Turner EH, et al. 2009. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ 339: b2981. DOI: 10.1136/bmj.b2981
47. Moser C, Krieg JC, Zihl J, Lautenbacher S. 2006. Attention and memory deficits in schizophrenia: the role of symptoms of depression. Cogn Behav Neurol 19: 150-156.
48. Mucci A, Piegari G, Galderisi S. 2008. Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemol Ment Health 4: 24.
49. Penades R, Gasto C, Boget T, Catalan R, Salamero M. 2001. Deficit in schizophrenia: the relationship between negative symptoms and neurocognition. Compr Psychiatry 42: 64-69.
50. Purdon SE, Malla A, Labelle A, LitW. 2001. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149.
51. Reitan RM. 1958. Validity of the trailmaking test as an indication of organic brain damage. Percept Mot Skills 8: 271-276.
52. Riedel M, Muller N, Spellmann I, et al. 2007a. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 257: 402-412.
53. Riedel M, Spellmann I, Strassnig M, et al. 2007b. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 257: 360-370.
54. Schmidt M. 1996. Rey Auditory Verbal Learning Test - A Handbook. Western Psychological Services: Los Angeles.
55. Schuurman PR, Bruins J, Merkus MP, Bosch DA, Speelman JD. 2002. A comparison of neuropsychological effects of thalamotomy and thalamic stimulation. Neurology 59: 1232-1239.
56. Smith RC, Infante M, Singh A, Khandat A. 2001. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol 4: 239-250.
57. Spohn HE, Strauss ME. 1989. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98: 367-380.
58. Spreen O, Benton AL. 1965. Comparative studies of some psychological tests for cerebral damage. J Nerv Ment Dis 140: 323-333.
59. Strauss ME. 1993. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull 19: 215-231.
60. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
61. Velligan DI, Newcomer J, Pultz J, et al. 2002. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239-248.
62. Vidailhet P, Danion JM, Chemin C, Kazes M. 1999. Lorazepam impairs both visual and auditory perceptual priming. Psychopharmacology (Berl) 147: 266-273.
63. Voruganti LP, Awad AG, Parker G, et al. 2007. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 96: 146-155.
64. Wiebel B, Happe A, Peikara F. 1995. Das Neuropsychologische Diagnostikprogramm TESTBAT. Psymed: Dulmen.
65. Wittorf A, Sickinger S, Wiedemann G, Klingberg S. 2008. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol 23: 271-282.
66. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472.
67. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2007. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89: 211-224.